9:00 am Preconference Virtual Networking
Overcoming Regulatory Restrictions at Home and Abroad
9:30 am FDA Regulation of Cannabinoid Pharmaceuticals – Breaking Down All Possible Routes to Approval
Synopsis
9:50 am The International Drug Control Landscape for Cannabinoid Derived Pharmaceuticals
Synopsis
10:10 am Rx and Non-Rx Cannabinoids: A Regulatory Framework for Market Access and Product Quality in Healthcare and Selfcare
Synopsis
10:40 am Live Presenter Q&A
11:00 am Morning Break & Virtual networking
11:20 am Case Study: Brazilian Cannabis Regulation and its Impact for the Companys’ Clinical Trials Pipeline
Synopsis
11:40 am Key Regulatory Takeaways in Developing a Cannabinoid Pharmaceutical Development Strategy
Synopsis
12:00 pm Live Presenter Q&A
Breaking Down Barriers to Investment
12:20 pm Panel Discussion: Dispelling Common Misconceptions About Biotech Funding and Applying this Understanding to Cannabinoid Pharmaceuticals
1:00 pm Lunch & Virtual Networking
1:55 pm
Efficiently Take your Cannabinoid Formulation from In Vivo/Vitro Testing into the Clinic, with Confidence
2:00 pm Assessing the Potential Clinical Value of the Next Hopefuls in Cannabinoid Pharmaceutical APIs: CBG, CBN and THCA
Synopsis
- Preclinical evidence for the use of novel minor cannabinoids
- Minor cannabinoid safety and toxicity
- Where is the clinical evidence?
2:20 pm Analyzing Clinical Data to Extract Insights into Clinical Endpoints and Mechanism of Action
Synopsis
• Tetra Biopharma is currently pursuing a variety of clinical programs employing inhaled synthetic cannabinoid
derived pharmaceuticals, including for pain and oncology indications
• Analysis, interpretation and comparison of data across programs also connects these and is invaluable for the
design of future studies and in decision making when it comes to future indications to pursue
2:40 pm Strategically Selecting New Indications to Pursue
Synopsis
• Which data can be used to inform future therapeutic indications to pursue
• Clinical trial data for expanding the indications of existing pharmaceuticals
• Regulatory considerations in cannabis-based pharmaceutical development